Victor Micati
Vorsitzender bei Oligomerix, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Albert Bourla | M | 62 | 31 Jahre | |
| James G. Moe | M | - |
Oligomerix, Inc.
 Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | 18 Jahre |
| David Dantzker | M | 80 |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.
Origin Life Sciences, Inc.
 Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | 18 Jahre |
| Douglas Lankler | M | 58 | 25 Jahre | |
| Eliot J. Davidowitz | M | - |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | 18 Jahre |
| William Erhardt | M | - |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | 4 Jahre |
| Michael Preston | M | 78 |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | 14 Jahre |
| Robert Foerster | M | - |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | - |
| Jerome Korten | M | 67 |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | 1 Jahre |
| Jack Pasini | M | - |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | 14 Jahre |
| Rady Johnson | M | 63 | 30 Jahre | |
| Alexander Dolgopolsky | M | - |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | 14 Jahre |
| Tony Brampton | M | 66 |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | 10 Jahre |
| Kathleen Bannon | F | - |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | - |
| Alan Talbert Silverman | M | - |
Monterey Institute of International Studies
| - |
| David J. Benjamin | M | - |
Monterey Institute of International Studies
| - |
| Jeffrey Bluestein | M | - |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | - |
| David B. Deniger | M | - |
Monterey Institute of International Studies
| - |
| John DeYoung | M | 61 | 33 Jahre | |
| Payal Sahni Becher | F | - | 27 Jahre | |
| Frederick L. A. Grauer | M | - |
Monterey Institute of International Studies
| - |
| Anatoly Shekhter | M | - |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | - |
| Victor Vasilets | M | - |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | - |
| Peter Vowden | M | - |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | - |
| Jason Martel | M | - |
Monterey Institute of International Studies
| - |
| Anna Vassilieva | F | - |
Monterey Institute of International Studies
| - |
| Jason Scorse | M | - |
Monterey Institute of International Studies
| - |
| Sander A. Flaum | M | 87 |
Monterey Institute of International Studies
| - |
| Douglas N. Durand | M | - |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| William Steere | M | 88 | 28 Jahre | |
| Ian Read | M | 71 | 41 Jahre | |
| Arthur Higgins | M | 68 | 3 Jahre | |
| David Shedlarz | M | 75 | 31 Jahre | |
| Andrew D. Rackear | M | 70 | 11 Jahre | |
| Constance J. Horner | F | 82 | - | |
| Alexander Denner | M | 54 | 4 Jahre | |
| Jeffrey H. Buchalter | M | 67 | 6 Jahre | |
| Jennifer Schroeder | F | - | 20 Jahre | |
| Craig Tooman | M | 58 | 5 Jahre | |
| Elizabeth Hanna | F | 59 |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | 4 Jahre |
| Martin MacKay | M | 68 | 14 Jahre | |
| Richard Young | M | 70 | 3 Jahre | |
| Thomas W. Fry | M | 79 | 3 Jahre | |
| Mohamed Roushdy | M | - | - | |
| Thomas F. Deuel | M | 89 | 3 Jahre | |
| Jacob M. Plotsker | M | 56 | 16 Jahre | |
| Joseph M. Danis | M | - | 10 Jahre | |
| Bob C. Salisbury | M | 80 | 8 Jahre | |
| Kenneth Zuerblis | M | 64 | 14 Jahre | |
| George Milne | M | 80 | 32 Jahre | |
| Charles H. Hill | M | 69 | 31 Jahre | |
| Dana George Mead | M | 88 | 12 Jahre | |
| Michael Brown | M | 83 | 16 Jahre | |
| M. Anthony Burns | M | 81 | 25 Jahre | |
| Franklin Raines | M | 74 | 11 Jahre | |
| Alan Levin | M | 62 | 20 Jahre | |
| Wyllie Cornwell | M | 76 | 23 Jahre | |
| Lee M. Greenberger | M | - | - | |
| Aby Buchbinder | M | 55 | 7 Jahre | |
| Michael Dunne | M | 64 | 17 Jahre | |
| David Simmons | M | 59 | 16 Jahre | |
| Paulash Mohsen | M | - | 14 Jahre | |
| Robert Clark | M | 64 | 29 Jahre | |
| Hua Gong | M | 57 | 10 Jahre | |
| Christopher Scully | M | 53 | 20 Jahre | |
| Baiyong Li | M | 56 | 12 Jahre | |
| Roger Leone | M | - | 14 Jahre | |
| Tariq Arshad | M | 54 | 12 Jahre | |
| Jeffrey Kent | M | 62 | 4 Jahre | |
| Nenad Sarapa | M | - | 6 Jahre | |
| Dawn Rogers | F | 59 | - | |
| Lit-Fui Lau | M | 62 | 10 Jahre | |
| Krishan K. Arora | M | 83 | 5 Jahre | |
| Richard Paulson | M | 56 | 9 Jahre | |
| Gary Seelhorst | M | 52 | 8 Jahre | |
| Scott Cheshareck | M | - | 16 Jahre | |
| Jean-Michael Halfon | M | 72 | 21 Jahre | |
| John W. Poyhonen | M | 64 | 7 Jahre | |
| Lisa Ricciardi | F | 64 | - | |
| Walter S. Hauck | M | 64 | 13 Jahre | |
| John F. Niblack | M | 85 | 35 Jahre | |
| Jean-Paul Vallès | M | - | 25 Jahre | |
| Robert Zerbe | M | 73 | 7 Jahre | |
| Gene Clapp | M | - | - | |
| Richard G. Minicus | M | - | - | |
| Warren R. Winter | M | - | 15 Jahre | |
| Thomas G. Gant | M | - | 6 Jahre | |
| Steven Ward | M | 64 | 15 Jahre | |
| Frank Sciavolino | M | 83 | 35 Jahre | |
| Julie A. Olson | M | - | 19 Jahre | |
| George W. Evans | M | 70 | 26 Jahre | |
| James R. Thomas | M | 73 | 19 Jahre | |
| Philip S. Burton | M | - | - | |
| Jay T. Goodwin | M | - | - | |
| Tim Bertram | M | 68 | 5 Jahre | |
| Samuel Yonren | M | - | - | |
| Michael Loechel | M | - | 11 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 97 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Victor Micati
- Persönliches Netzwerk
